Using highly purified myeloma cells from patient bone marrow, we established human-murine myeloma chimeras in severe combined immunodeficiency (SCID) mice and documented secretion of monoclonal human immunoglobulins (Hulgs) in the mice for up to 299 days. Monoclonality of circulating Hulgs was found only when highly purified myeloma cells were injected intraperitoneally. In contrast, injection of unfractionated myeloma marrow led to the development of polyclonal Hulgs in the SClD mice. The criteria for myeloma engraftment included prolonged presence of monoclonal Hulgs in the sera of SClD mice and/or detection of human myeloma cells in their tissues by immunohistochemical examination. Ninety-one percent (10/11) of the fresh HE STUDY of murine models has yielded substantial T information on both the occurrence of asymptomatic monoclonal gammopathies without obvious tumor formation and the development of plasma cell neoplasms.lV2 Most of these studies have used murine plasma cell neoplasms in BALB-C mice3g4 as a model for development of the human disease. Other investigators have also used mouse models in an attempt to reproduce some aspects of other human clinical syndromes associated with monoclonal gammopathies.5p6 However, there have been no prior reports of successful attempts to produce human-murine chimeras with fresh human multiple myeloma (MM) cells. A model of this type would improve the ability to study human myeloma biology and might be of value for studying therapeutic manipulation of fresh human myeloma cells in vivo.
Using highly purified myeloma cells from patient bone marrow, we established human-murine myeloma chimeras in severe combined immunodeficiency (SCID) mice and documented secretion of monoclonal human immunoglobulins (Hulgs) in the mice for up to 299 days. Monoclonality of circulating Hulgs was found only when highly purified myeloma cells were injected intraperitoneally. In contrast, injection of unfractionated myeloma marrow led to the development of polyclonal Hulgs in the SClD mice. The criteria for myeloma engraftment included prolonged presence of monoclonal Hulgs in the sera of SClD mice and/or detection of human myeloma cells in their tissues by immunohistochemical examination. Ninety-one percent (10/11) of the fresh HE STUDY of murine models has yielded substantial T information on both the occurrence of asymptomatic monoclonal gammopathies without obvious tumor formation and the development of plasma cell neoplasms.lV2 Most of these studies have used murine plasma cell neoplasms in BALB-C mice3g4 as a model for development of the human disease. Other investigators have also used mouse models in an attempt to reproduce some aspects of other human clinical syndromes associated with monoclonal gammopathies.5p6 However, there have been no prior reports of successful attempts to produce human-murine chimeras with fresh human multiple myeloma (MM) cells. A model of this type would improve the ability to study human myeloma biology and might be of value for studying therapeutic manipulation of fresh human myeloma cells in vivo.
Since the initial description of the severe combined immunodeficiency (SCID) syndrome in mice,' several studies have been published related to the use of such mice as animal models for a variety of human disease^,^-^^ including several hematologic malignan~ies.'~-*~ Because SCID mice are deficient in mature T and B lymphocytes,21,22 we hypothesized that they might provide an excellent in vivo model in which to establish human myeloma chimeras. This report documents characteristics of this model.
MATERIALS AND METHODS

Patients
Tumor cells from 11 patients with MM were used in this study. All bone marrows (BMs) were obtained from patients registered in the Southwest Oncology Group myeloma studies, and samples were submitted to the myeloma research and phenotyping laboratories of the University of Arizona. The patients included six women and five men ranging in age from 34 to 76 years ( Table 1) . Nine of the patients had not received prior treatment. The group included one patient with stage I myeloma, two with stage 11, and 8 with stage 111 by Durie-Salmon staging criteria? BM specimens from 10 patients with MM as well as a tumor biopsy from a breast plasmacytoma in an MM patient were processed for injection into the SCID mice. Peripheral blood lymphocytes from an ovarian carcinoma patient (patient 12) and ascites fluid known to contain malignant cells from a woman with non-Hodgkin's lymphoma (patient 13) were used as nonmyeloma controls for these studies (Table 2) . purified myeloma specimens engrafted in the SClD mice. Fifty-five percent (6/11) of the patient samples resulted in human B-cell grafts, and 45% (5/11) were identifiable as human myeloma chimeras. Pathologic studies showed that most human plasmacytes were located in the peritoneal cavity but metastatic infiltrates were also found in other organs in 69% of the SCID-human myeloma chimeras. This chimeric model should provide a useful tool for characterization of growth modulation and microenvironmental interactions as well as a means of testing new therapeutic approaches to multiple myeloma.
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Cell Preparation
BM aspirates and tumor samples from MM patients were processed and injected into SCID mice within 18 to 24 hours after the specimens were obtained from the patients. Myeloma cells were purified as described e l s e~h e r e .~~~~ Briefly, heparinized BM samples were centrifuged at 550g for 15 minutes on a FicollHypaque (ICN Flow, Costa Mesa, CA) gradient. BM mononuclear cells were collected from the interface and fractionated further on a Percoll (Pharmacia-LKB Co, Uppsala, Sweden) discontinuous density gradient. Cells banding at interfaces between 45% and 50% Percoll were collected. Sheep red blood cells, were used for rosette depletion of T cells. Non-E-rosetting cells were treated with antimyelomonocytic monoclonal antibody (MoAb) Leu M1 (anti-CD15) (Becton Dickinson, Mountain View, CA) plus rabbit complement. The cells were washed three times with medium (described below). The purified population consisted of 92% to 100% human myeloma cells. Thus, cells from three sequential levels of purification were available for injection into SCID mice: BM mononuclear cells, non-E-rosetting cells, and purified MM cells.
An extramedullary plasmacytoma of the breast from a patient with A chain Bence Jones protein MM (patient 9) was processed by mechanical techniques2s followed by treatment with hypo-osmolar medium and enzymatic cell disaggregation.26 The suspension was passed through two layers of cotton gauze and washed twice in medium.
Final cell suspensions were counted in a hemocytometer and viability determined by trypan blue exclusion. Wright-Giemsa staining was used to evaluate cell morphology. 
Animals, Cell Inoculation, and Mice Sera Collection
The original SCID mouse breeding pairs were obtained from The Jackson Laboratory (Bar Harbor, ME) and thereafter they were housed and maintained under specific pathogen-free conditions, with trimethoprim sulfamethoxazole in the drinking water, at the Animal Resources Facility of the University of Arizona Health Science Center. Adult male and female SCID mice (4 to 10 weeks of age) with less than 1 pg/mL of mouse immunoglobulin (Ig) in the serum were used for inoculation. SCID mice were injected intraperitoneally (IP) with 2.8 to 10 X 106viable cells in 0.1 to 0.2 mL of phosphate buffered saline (PBS), pH 7.4, using a 25-gauge needle attached to a 1-mL syringe. All mice in the myeloma group were injected with purified MM cells, with the exceptions of the group for patient 11 in which BM mononuclear cells were used and the group for patient 5 in which mice were injected either with BM mononuclear cells, with non-E-rosetting cells, or with purified MM cells. Peripheral blood lymphocytes from patient 12 were injected IP at 5 X lo6 viable lymphoid cells. Ascites fluid cells from patient 13 were injected at 5 x 106 viable lymphoid cells. Mice injected with PBS alone were used as negative controls. For serial serum sampling mice were bled from the retro-orbital sinus. Blood was centrifuged at 800g for 15 minutes at room temperature and sera collected and stored at 20°C until analysis. In accord with the guidelines of the University of Arizona Animal Subjects Committee, animals were killed before they developed large tumor burdens or died of myeloma.
MoAbs and Purified Proteins
Unconjugated and alkaline phosphatase-conjugated antibodies specific for either human IgG or K or A light chains, and for mouse For personal use only. on October 3, 2017. by guest www.bloodjournal.org From IgG were purchased from TAGO Inc (Burlingame, CA). Antibodies specific for human IgM, IgA, or multivalent human immunoglobulin (HuIg) (G + A + M + E + D) were purchased from ATAB, Atlantic Antibodies (Scarborough, ME).
Enzyme-Linked Immunosorbent Assays (ELISA)
Flat bottom 96-well microplates were coated with 1 pg/mL (100 pL/well) of heavy chain-specific MoAb and incubated overnight at 4°C; washed twice with tris buffer saline (TBS) (tris base 50 mmoliL, sodium chloride 200 mmoliL, pH 7.5) containing 0.05% (vol/vol) of Tween 20, and an additional time with TBS. Blocking was achieved with 200 pL/well of 1% bovine serum albumin (BSA) in TBS for 30 minutes at 37°C and then washed twice with TBS. Serial dilutions of samples in TBS-BSA (100 pL/well) were incubated in triplicate for 30 minutes at 37°C. After three washes, pretitered alkaline phosphatase-conjugated specific second antibody (100 pLiwel1) was added (1 pg/mL in TBS-BSA), incubated for 30 minutes at 3 7 T , and washed three times. Substrate solution containing p-nitro-phenyl-phosphate (Sigma Chemical Co) at 1 mg/mL (100 pL/well) in carbonate buffer (0.1 mol/L, pH 9.6) was added and incubated for 30 minutes at 37°C. Optical density of the wells at 410 nm was determined with a Dynatech MR 600 plate reader (Dynatech Laboratories Inc, Alexandria, VA).
Serial dilutions of either purified HuIgG (TAGO Inc) or purified HuIgA (Sigma Chemical Co) in TBS-BSA were used as controls to establish a standard curve for each plate. Pooled normal SCID mouse serum was used as a negative control. HuIg levels were calculated by interpolating readings from mean value of each triplicate sample on the standard HuIgG curve with a regression coefficient (r) equal to or greater than 0.97. Each sample was tested in a similar manner, using either K or A light chain-specific alkaline phosphatase-conjugated MoAbs as a second antibody in wells precoated with antibodies specific for each heavy chain (a, 7 , or p) and to a polyspecific antibody.
For the analysis of murine IgG (MoIgG) microplates were prepared similar to those for HuIg. Similar blocking and washing steps were used, however, the wells were coated with goat anti-MoIgG. Identical incubation time, temperatures, and substrate were used. Serum samples were diluted serially in TBS-BSA and added to the wells (100 pL/well). Purified mouse Igs (Caltag, San Francisco, CA) were diluted in TBS-BSA and used for the standard curve and pooled IgG-depleted SCID mouse serum was used as a negative control.
HuIg ELISA.
Mouse lg ELISA.
Biochemical Criteria for Engraftment
Using serum levels of HuIgs in the SCID mice as a marker of engraftment, we defined SCID-human B-cell chimeric animals by the following criteria: (1) continuously increasing values of HuIgs in mouse sera (positive slope of the HuIgs versus time curve); or (2) if the HuIgs versus time curve showed a neutral or negative slope, the actual value of HuIg at any specific time point had to be significantly greater than the calculated value at the same time point as compared with the half-life of the particular Ig in the SCID mice, and considering as an initial protein load the value of HuIg at the peak of the actual curve. Among the mice considered positive for polyclonal human B-cell engraftment, only those that showed monoclonality were considered positive for the myeloma engraftment.
Tumor Pathology and Phenotyping
A gross autopsy examination was performed on each animal. Excised tissues were both snap frozen and fixed in 10% buffered formalin. Frozen sections were analyzed for immunophenotyping and fixed sections were used for conventional histology studies.
Paraffin-embedded sections were stained with hematoxylineosin (H-E). Slide touch preparations of sectioned tissues (spleen, lymph nodes, liver) were air-dried and stained with Wright's stain.
Additional sections were used for immunohistochemical staining for human cytoplasmic Igs using a previously described immunoperoxidase method with avidin-biotin bridging.*' Primary antibodies applied included those against K and A light chains, p, 7, a, and 6 heavy chains (DAKO, Santa Barbara, CA). Tissue sections (including mouse plasma cells) from a control group of nontumor-bearing SCID mice (n = 6) were evaluated with the various antihuman Ig antibodies and were nonreactive. This confirms noncross-reactivity of mouse versus human tissues using these antibodies.
Histopathologic Criteria for Engraftment
Animals that showed clusters of plasmacytes and/or lymphoplasmacytoid cells by H-E staining were consider suspicious for engraftment. Positive immunophenotyping using MoAbs to the human heavy and light chains of Igs was required to establish that the clusters were of human origin and that engraftment had occurred.
RESULTS
A total of 67 SCID mice were used in these experiments. Overall results of these studies are summarized in Table 2 . The SCID population included 48 mice injected with human cells, 5 mice that served as a PBS-injected negative control group, and 14 mice used to establish the human Ig clearance curves. Of the 48 mice injected with human cell samples, 39 were injected with cells from MM patients, including 35 mice injected with BM cells from 10 MM patients and 4 mice injected with plasmacytes obtained from an extramedullary plasmacytoma. A n y given mouse only received cells from a single donor preparation. The remaining nine SCID mice served as a polyclonal engraftment control group: one was injected with peripheral blood lymphocytes from an ovarian carcinoma patient (patient 12 in Table 2 ) and eight with tumor cells from ascites of a patient with non-Hodgkin's lymphoma (patient 13 in Table  2 ).
SCID Serum Human Ig Marker
The mean calculated half-life for passively transferred HuIgG in the SCID mouse was 11.2 days (SD = 1.3). The clearance curve had the regression coefficient r = -.9946, and fitted in the equation: y = A eBx in which A = 207045 and B = -0.061.
Of the mice injected with myeloma cells (from patients 1 to 11 in Table 2 ), 27/39 (69%) developed human Ig serum levels of 5 ng/mL or more for at least 98 days. Monoclonality was established in 21/39 (54%). Overall 17/39 (44%) met the criteria for biochemical engraftment for human B cells but only 13/39 (33%) met the biochemical criteria of engraftment for human myeloma. Table 2 also summarizes the kinetics of HuIg in SCID mice for all 13 patient samples studied. In five of nine groups of MM-injected mice showing HuIg, the peak HuIg level occurred more than 30 days after tumor cell injection consistent with clonal expansion after engraftment.
Injection of cells from 9 of the 11 fresh myeloma samples resulted in the development of HuIgs in the SCID mice (82%) (Figs 1A and B) . Six of 11 (55%) patient samples met Table 2) .
Peripheral blood lymphocytes from a patient with ovarian carcinoma (patient 12 in Table 2 ; Fig 1B) produced polyclonal HuIg in the SCID mice, fulfilling biochemical criteria of engraftment for human B cells. Cells from ascites from a non-Hodgkin's lymphoma patient (patient 13) were injected in 8 mice but none of them developed detectable levels of serum HuIg. lymph nodes 1/16 (6%); and mediastinum 1/16 (6%). Pathologic evidence of BM involvement was not identified in any of the mice autopsied. The murine autopsy studies showed that microscopic foci of plasmacytes arose for 9/ 11 patients studied.
Representative mice from each suspicious positive engraftment in each patient group were immunophenotyped for cytoplasmic HuIg (Fig 3) . Seven of nine mice positive by H-E (78%) had human monoclonality established by immunphenotyping ( Table 2) . One of them (from patient 9) had only A light chain identified in the myeloma cells.
Mice injected with cells from patient 12 did not show positivity on H-E staining, however, mice injected with cells from patient 13 had a pattern of plasmacyte growth in infradiaphragmatic lymph nodes, spleen, and mediastinum. The latter clusters were determined to be of human origin but were polyclonal.
Pathologic Findings Expression of Engrafiment
None of the mice died of progressive tumor or had gross evidence of tumor at necropsy. In the group of mice injected with myeloma cells 16 of 33 (48%) mice studied microscopically had clusters of plasmacytes present (Fig 2) . The majority of the tumor cell clusters were found in the peritoneal cavity as the only finding in 7/16 (44%) or along with infiltrating plasmacytes in other organs. Among the infiltrated organs were: spleen 5/16 (31%); liver 3/16 (19%); kidneys 2/16 (13%); pancreas 1/16 (6%); and Biochemical criteria of relevant monoclonal Ig engraftment were achieved in mice receiving myeloma cells from 5/11 patients (45%) and histopathologic criteria for engraftment were present in 6/11 patients (54%). Either biochemical or histopathologic criteria for engraftment were present in 10/11 (91%). Coexistence of biochemical and histopathologic criteria for engraftment was present only in mice receiving purified myeloma cells from patient sample 3. From   Fig 2. H-E preparation from a parafin-embedded section of a mouse injected with purified myeloma cells from patient 3. Plasmacytomas were located on the surface of the peritoneal cavity (arrow). Lower power magnification (A) and higher magnification (6) of the same lesional tissue.
Lack of both biochemical and histopathologic criteria for
engraftment was present only in micc injcctcd with myeloma cclls from patient 7.
Four paticnts samplcs failed to achicvc biochcmical criteria of engraftmcnt but had histopathologic critcria for cngraftmcnt (4,6,9, and IO). Two paticnts samplcs (1 and 2) achicvcd biochcmical critcria of cngraftmcnt but not histopathologic criteria for engraftmcnt. Two othcr patient samplcs achicvcd biochemical critcria of cngraftment but lcsional tissue was not idcntificd (paticnt 5) or immunphcnotyping was not performed (patient 8). Cclls from paticnt 11 achicved histopathologic critcria for cngraftmcnt but polyclonality was shown in thc HuIg studics.
Biochemical and/or histopathologic critcria for cngraftmcnt were not achicved in any mice injected with PBS alone (negative control group). In the polyclonal control group, micc injected with peripheral blood mononuclear cells from paticnt 12 achieved biochcmical but not histopathologic criteria for engraftment and mice injected with ascitcs cells from patient 13 achievcd histopathologic critcria for engraftment in a polyclonal manner but not biochemical criteria of engraftment.
Hitman Ig Phenotype Correlations
All mice injected with cells from MM paticnts as purified MM cells or non-E-rosetting cclls werc monoclonal and maintained thc same phcnotypc as detected in the patient. Patient 11 had Bcnce Jones MM expressing K light (K) 
DISCUSSION
The results of this study provide evidence that relatively long-term chimeric engraftment of purified human MM cells can be achieved in SCID mice. Overall, serial evaluation of serum human monoclonal Ig proved to be most useful for providing confirmation of engraftment and of the duration of graft viability. Inasmuch as SCID mice proved to clear human Igs much more slowly than normal mice, we considered it necessary to determine normal human Ig clearance in SCID mice to have a guideline against which we could establish whether the persisting human Ig levels in the SCIDs represented more than the normal slow clearance of passively transferred human Igs derived from myeloma cells undergoing cytolysis. However, most instances of engraftment showed peak serum levels of human Igs in the SCID mouse at 1 month or more after receiving the tumor cell injection consistent with clonal expansion. We did not determine the overall survival time of the SCID-myeloma chimeras because they were killed at defined intervals for histologic evaluation. In one instance (with cells from patient 1) a sustained human myeloma graft persisted for at least 299 days. In no instance did overtly progressive myeloma develop and result in the death of the animals during the period of observation. However, it is important to point out that the University of Arizona Animal Subjects Committee requires animals to be euthanized before they develop advanced tumors and survival was not an endpoint in this study. Whereas serum marker studies were useful in SCID mice receiving tumor cells from patients with myeloma who had serum M-component peaks, they were not of value with respect to the two patients with Bence Jones (light chain) myeloma included in these studies. Urine was not collected on these specific SCID recipients and only histopathologic studies could be used to evaluate engraftment. Even in patients, myeloma light chains are normally not detectable in serum because of rapid renal clearance (in the absence of renal failure) of these low molecular weight Ig chains.
The use of histopathology and particularly immunohistochemistry provided a valuable confirmation of engraftment in some of the SCID mice. Whereas the grafts seemed to persist particularly in the peritoneal cavity (where cells were injected), there was nonetheless evidence of metastatic spread to lymph nodes and various visceral organs in some of the SCID mice. It was of interest that BM involvement was not detected in any of the SCID mice that engrafted with myeloma. This phenomenon is reminiscent of experimental myeloma in BALB-C induced with either IP mineral oil or pristane.' Such mice primarily have IP myeloma present, and marrow involvement is not part of the disease pattern. Whether IP growth of plasma cells is a function of route of injection or caused by a biological difference in homing sites in mice versus humans bearing plasma cell neoplasms cannot be determined from our studies.
Inasmuch as myelomatous takes occurred with purified cells from most myeloma patients studied, it was difficult to identify prognostic factors associated with engraftment. For example, there was no correlation between myeloma stage or treatment status and engraftment. The absence of expression of CD56 in a subfraction of cells from the human myeloma cell line 8226 has recently been presented by Grogan et al as being associated with better takes of this long-term line in SCID mice.30 CD56 has been characterized as a neuronal cellular adhesion molecule (NCAIVI).~~ It is also normally expressed on natural killer (NK) cells. The one myeloma patient tested whose cells lacked CD56 did engraft in the SCID mouse, but so did those of other patients whose cells were CD56 positive. However, the engraftment from this IgA myeloma that was NCAM negative did have the most rapid growth rate and largest tumor mass. Nonetheless, CD.56 is expressed on the tumor cells of most patients with progressive MM.32 The significance of the expression of NCAM on myeloma cells from most patients but the absence on normal plasma cells remains obscure.
SCID mice are known to engraft with peripheral blood and lymphoid cells and develop the normal array of human serum Igs and T cells if the human cell donor is negative for Epstein-Barr virus (EBV) infection. In contrast, SCIDs injected with lymphoid cells from donors who are EBV positive generally develop fatal B-cell lymphomas of human lymphoid rigi in.'^,^^ We probed for the EBV g e n~m e~~.~~ in four patients but did not find it expressed in myeloma cells despite the fact that their cells engrafted in the SCID mice (data not shown).
It proved essential to purify myeloma cells before injection in the mice because in those instances in which unfractionated marrow was administered, polyclonal B-cell takes developed in the recipient mice. This is of interest because normal B-cell function is characteristically depressed in patients with myeloma and they have low levels of Igs of the uninvolved classes and light chain type. The evolution of polyclonal B-cell takes from unfractionated MM indicates that a significant number of normal B-cell progenitors are present in the patient's marrow, but are inhibited from proliferating by the myeloma and perhaps by accessory cells. This form of inhibition of normal B-cell function is also seen in BALB-C myeloma even though the disease does not involve the marrow.34 We speculate that the profound depletion of normal murine immunocytes and perhaps some accessory cells in the SCID mouse interrupts For personal use only. on October 3, 2017. by guest www.bloodjournal.org From the immunoregulatory circuits that myeloma usually makes use of to inhibit normal polyclonal B-cell proliferation. Thus, the SCID model may prove useful for further defining the immunoregulatory abnormality responsible for the B-cell immunodeficiency state observed in both murine and human myeloma. Clearly this did not develop in the SCID mice that received unfractionated marrow from myeloma patients as they expressed polyclonal human Igs in their serum. In one of these patients purified myeloma cells as well as unfractionated marrow cells were injected into different SCID mice. Only the purified myeloma cells injected gave rise to evidence for an IgG K myeloma engraftment, whereas use of unfractionated marrow resulted in a polyclonal lymphoid take.
The explanation for eventual myeloma graft failure in many SCID mice that engrafted with myeloma is not clear. Whereas SCID mice lack B and T cells, they have macropha g e~~~,~~ and NK ~e l l s .~' ,~~ Perhaps with further depletion of the SCID immune system (eg, with antisera directed against murine macrophages or NK cells), progressive myeloma growth would be observed in more of the animals. Such studies may further clarify the biology of human MM and potentially provide the basis for new therapeutic approaches as well.
